OBJECTIVE We evaluated baseline characteristics of participants with early-onset type 2 diabetes (T2D) from the SURPASS program and tirzepatide’s effects on glycemic control, body weight (BW), and cardiometabolic markers. RESEARCH DESIGN AND METHODS This post hoc analysis compared baseline characteristics and changes in mean HbA1c, BW, waist circumference (WC), lipids, and blood pressure (BP) in 3,792 participants with early-onset versus later-onset T2D at week 40 (A Study of Tirzepatide [LY3298176] in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone [SURPASS-1], A Study of Tirzepatide [LY3298176] Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes [SURPASS-2]) or week 52 (A Study of Tirzepatide [LY3298176] Versus Insulin Degludec in Participants With Type 2 Diabetes [SURPASS-3]). Analyses were performed by study on data from participants while on assigned treatment without rescue medication in case of persistent hyperglycemia. RESULTS At baseline in SURPASS-2, participants with early-onset versus later-onset T2D were younger with longer diabetes duration (9 vs. 7 years, P < 0.001) higher glycemic levels (8.5% vs. 8.2%, P < 0.001), higher BW (97 vs. 93 kg, P < 0.001) and BMI (35 vs. 34 kg/m2, P < 0.001), and a similarly abnormal lipid profile (e.g., triglycerides 167 vs. 156 mg/dL). At week 40, similar improvements in HbA1c (−2.6% vs. −2.4%), BW (−14 vs. −13 kg), WC (−10 vs. −10 cm), triglycerides (−26% vs. −24%), HDL (7% vs. 7%), and systolic BP (−6 vs. −7 mmHg) were observed in both subgroups with tirzepatide. CONCLUSIONS Despite younger age, participants with early-onset T2D from the SURPASS program had higher glycemic levels and worse overall metabolic health at baseline versus those with later-onset T2D. In this post hoc analysis, similar improvements in HbA1c, BW, and cardiometabolic markers were observed with tirzepatide, irrespective of age at T2D diagnosis. Future studies are needed to determine long-term outcomes of tirzepatide in early-onset T2D.

中文翻译：

---

早发 2 型糖尿病和替西帕肽治疗：来自 SURPASS 临床试验计划的事后分析

目的 我们评估了 SURPASS 项目中早发型 2 型糖尿病 (T2D) 参与者的基线特征以及替西帕肽对血糖控制、体重 (BW) 和心脏代谢标志物的影响。研究设计和方法 这项事后分析比较了 3,792 名早发型与晚发型 T2D 参与者在第 40 周时的基线特征和平均 HbA1c、BW、腰围 (WC)、血脂和血压 (BP) 的变化（A替泽帕肽 [LY3298176] 在仅靠饮食和运动无法控制的 2 型糖尿病参与者中的研究 [SURPASS-1]，替泽帕肽 [LY3298176] 与每周一次索马鲁肽作为二甲双胍附加治疗在 2 型糖尿病参与者中的研究 [ SURPASS-2]）或第 52 周（替泽帕肽 [LY3298176] 与德谷胰岛素在 2 型糖尿病参与者中的研究 [SURPASS-3]）。分析是通过研究参与者在持续高血糖的情况下在没有救援药物的情况下接受指定治疗的数据来进行的。结果 在 SURPASS-2 的基线时，早发性 T2D 参与者与晚发性 T2D 参与者相比更年轻，糖尿病病程较长（9 年 vs. 7 年，P < 0.001），血糖水平较高（8.5% vs. 8.2%，P < 0.001）。 0.001），较高的体重（97 vs. 93 kg，P < 0.001）和BMI（35 vs. 34 kg/m2，P < 0.001），以及类似的异常脂质谱（例如，甘油三酯167 vs. 156 mg/ dL）。第 40 周时，HbA1c（-2.6% vs. -2.4%）、体重（-14 kg vs. -13 kg）、WC（-10 cm vs. -10 cm）、甘油三酯（-26% vs. -24 %）、HDL（7% vs. 7%）和收缩压（−6 vs. -7 mmHg）在使用替泽帕肽的两个亚组中均观察到。结论 尽管年龄较小，但 SURPASS 项目中的早发性 T2D 参与者与晚发性 T2D 参与者相比，基线时血糖水平较高，总体代谢健康状况较差。在这项事后分析中，无论 T2D 诊断时的年龄如何，使用替泽帕肽都观察到 HbA1c、BW 和心脏代谢标志物的类似改善。未来的研究需要确定替西帕肽治疗早发性 T2D 的长期结果。